Brief: Virpax Pharmaceuticals Receives Notice Of Delisting From Nasdaq
29/12/2022 21:47
Dec 29 (Reuters) - Virpax Pharmaceuticals Inc VRPX.O :
* VIRPAX PHARMACEUTICALS INC - ON DECEMBER 22, RECEIVED
NOTICE OF
DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR
STANDARD FROM NASDAQ
Source: (https://bit.ly/3hXL0ot)
Further company coverage: VRPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Virpax Pharmaceuticals
See all newsVirpax Pharma plunges as Nasdaq delisting looms
Brief: Virpax Pharmaceuticals Files For Offering On Best Efforts Basis Up To 2.4 Million Shares Of Common Stock
Brief: Virpax receives positive Probudur™ results for dose range study
Brief: Virpax Looking To Use Met To Develop Intranasal Covid Vaccine
Brief: Virpax Confirms Positive Results With Us Army With Probudur™ For Combat Care Study